脑膜炎球菌流行病学史中潜藏的重要教训。

IF 5.5 3区 医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-04-04 DOI:10.1080/14760584.2024.2329618
Ray Borrow, Jamie Findlow
{"title":"脑膜炎球菌流行病学史中潜藏的重要教训。","authors":"Ray Borrow, Jamie Findlow","doi":"10.1080/14760584.2024.2329618","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The epidemiology of invasive meningococcal disease (IMD), a rare but potentially fatal illness, is typically described as unpredictable and subject to sporadic outbreaks.</p><p><strong>Areas covered: </strong>Meningococcal epidemiology and vaccine use during the last ~ 200 years are examined within the context of meningococcal characterization and classification to guide future IMD prevention efforts.</p><p><strong>Expert opinion: </strong>Historical and contemporary data highlight the dynamic nature of meningococcal epidemiology, with continued emergence of hyperinvasive clones and affected regions. Recent shifts include global increases in serogroup W disease, meningococcal antimicrobial resistance (AMR), and meningococcal urethritis; additionally, unvaccinated populations have experienced disease resurgences following lifting of COVID-19 restrictions. Despite these changes, a close analysis of meningococcal epidemiology indicates consistent dominance of serogroups A, B, C, W, and Y and elevated IMD rates among infants and young children, adolescents/young adults, and older adults. Demonstrably effective vaccines against all 5 major disease-causing serogroups are available, and their prophylactic use represents a powerful weapon against IMD, including AMR. The World Health Organization's goal of defeating meningitis by the year 2030 demands broad protection against IMD, which in turn indicates an urgent need to expand meningococcal vaccination programs across major disease-causing serogroups and age-related risk groups.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The important lessons lurking in the history of meningococcal epidemiology.\",\"authors\":\"Ray Borrow, Jamie Findlow\",\"doi\":\"10.1080/14760584.2024.2329618\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The epidemiology of invasive meningococcal disease (IMD), a rare but potentially fatal illness, is typically described as unpredictable and subject to sporadic outbreaks.</p><p><strong>Areas covered: </strong>Meningococcal epidemiology and vaccine use during the last ~ 200 years are examined within the context of meningococcal characterization and classification to guide future IMD prevention efforts.</p><p><strong>Expert opinion: </strong>Historical and contemporary data highlight the dynamic nature of meningococcal epidemiology, with continued emergence of hyperinvasive clones and affected regions. Recent shifts include global increases in serogroup W disease, meningococcal antimicrobial resistance (AMR), and meningococcal urethritis; additionally, unvaccinated populations have experienced disease resurgences following lifting of COVID-19 restrictions. Despite these changes, a close analysis of meningococcal epidemiology indicates consistent dominance of serogroups A, B, C, W, and Y and elevated IMD rates among infants and young children, adolescents/young adults, and older adults. Demonstrably effective vaccines against all 5 major disease-causing serogroups are available, and their prophylactic use represents a powerful weapon against IMD, including AMR. The World Health Organization's goal of defeating meningitis by the year 2030 demands broad protection against IMD, which in turn indicates an urgent need to expand meningococcal vaccination programs across major disease-causing serogroups and age-related risk groups.</p>\",\"PeriodicalId\":12326,\"journal\":{\"name\":\"Expert Review of Vaccines\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14760584.2024.2329618\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2329618","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:侵袭性脑膜炎球菌病(IMD)是一种罕见但可能致命的疾病,其流行病学通常被描述为不可预测和偶发性爆发:专家观点:在脑膜炎球菌特征和分类的背景下,研究了过去约 200 年间脑膜炎球菌流行病学和疫苗使用情况,以指导未来的脑膜炎球菌病预防工作:专家观点:历史和当代数据凸显了脑膜炎球菌流行病学的动态性质,高侵袭性克隆和受影响地区不断涌现。最近的变化包括全球 W 血清群疾病、脑膜炎球菌抗菌药耐药性 (AMR) 和脑膜炎球菌尿道炎的增加;此外,在取消 COVID-19 限制后,未接种疫苗的人群再次发病。尽管发生了这些变化,但对脑膜炎球菌流行病学的仔细分析表明,A、B、C、W 和 Y 血清群始终占主导地位,婴幼儿、青少年/年轻成人和老年人的 IMD 感染率较高。目前已有针对所有 5 个主要致病血清群的明显有效的疫苗,预防性使用这些疫苗是抗击 IMD(包括 AMR)的有力武器。世界卫生组织到 2030 年消除脑膜炎的目标要求广泛预防 IMD,这反过来又表明迫切需要在主要致病血清群和与年龄相关的风险群体中扩大脑膜炎球菌疫苗接种计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The important lessons lurking in the history of meningococcal epidemiology.

Introduction: The epidemiology of invasive meningococcal disease (IMD), a rare but potentially fatal illness, is typically described as unpredictable and subject to sporadic outbreaks.

Areas covered: Meningococcal epidemiology and vaccine use during the last ~ 200 years are examined within the context of meningococcal characterization and classification to guide future IMD prevention efforts.

Expert opinion: Historical and contemporary data highlight the dynamic nature of meningococcal epidemiology, with continued emergence of hyperinvasive clones and affected regions. Recent shifts include global increases in serogroup W disease, meningococcal antimicrobial resistance (AMR), and meningococcal urethritis; additionally, unvaccinated populations have experienced disease resurgences following lifting of COVID-19 restrictions. Despite these changes, a close analysis of meningococcal epidemiology indicates consistent dominance of serogroups A, B, C, W, and Y and elevated IMD rates among infants and young children, adolescents/young adults, and older adults. Demonstrably effective vaccines against all 5 major disease-causing serogroups are available, and their prophylactic use represents a powerful weapon against IMD, including AMR. The World Health Organization's goal of defeating meningitis by the year 2030 demands broad protection against IMD, which in turn indicates an urgent need to expand meningococcal vaccination programs across major disease-causing serogroups and age-related risk groups.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Expert Review of Vaccines
Expert Review of Vaccines 医学-免疫学
CiteScore
9.10
自引率
3.20%
发文量
136
审稿时长
4-8 weeks
期刊介绍: Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
期刊最新文献
Hookworm vaccines: current and future directions. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. Estimating the time required to reach HPV vaccination targets across Europe. Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024. Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1